Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus
about
Molecular mechanism of action of metformin: old or new insights?Diabetes mellitus and metformin in hepatocellular carcinomaPatient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XRMetformin and metabolic diseases: a focus on hepatic aspectsInsulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study.Metformin-associated lactic acidosis presenting as an ischemic gut in a patient who then survived a cardiac arrest: a case report.Metformin's contraindications should be contraindicated.Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended eventProstate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research.Clinical evaluation of Dyslipidemia among type II diabetic patients at Public hospital Penang, Malaysia.Energy restriction and potential energy restriction mimetics.Metformin use and mortality in ambulatory patients with diabetes and heart failure.New steroid derivative with hypoglycemic activity.Effect of Aloe barbadensis Mill. formulation on Letrozole induced polycystic ovarian syndrome rat modelMetformin as an energy restriction mimetic agent for breast cancer preventionMetabolic Syndrome and Breast Cancer Risk: Is There a Role for Metformin?Outcome of severe lactic acidosis associated with metformin accumulation.A rare cause of severe lactic acidosis.The metabolic syndrome and risk of chronic kidney disease: pathophysiology and intervention strategies.Update on Safety Issues Related to Antihyperglycemic TherapyInsulin-sensitisers in the treatment of polycystic ovary syndrome.Metformin-induced lactic acidosis: a case seriesRole of metformin in the management of polycystic ovary syndrome.Treatment of diabetes in the elderly. Addressing its complexities in this high-risk group.Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus.Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.Clinical presentation and treatment of type 2 diabetes in children.Standards of medical care in diabetes--2009.The association of plasma lactate with incident cardiovascular outcomes: the ARIC Study.Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality.Insulin resistance postburn: underlying mechanisms and current therapeutic strategies.The role of hyperglycemia in burned patients: evidence-based studies.Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment.Survey of current medical treatments for childhood-onset type 2 diabetes mellitus in Japan.The role of serum lactate in the acute care setting.Metabolic Surgery for Type 2 Diabetes in Patients with a BMI of <35 kg/m(2): A Surgeon's Perspective.Unleash metformin: reconsideration of the contraindication in patients with renal impairment.Metformin: risk-benefit profile with a focus on cancer.Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure.
P2860
Q22252798-77C04850-C9CB-457E-AE47-95D5221D93D5Q26741205-4F10128B-A4C2-4EDE-9D18-FA90D0C8F02BQ26766404-858A11A7-AFB8-4A89-AE38-19AC1D08C1FDQ28082736-CD20DC8E-F64E-46B6-9A76-6F32E4C3D51AQ33247492-DDFAC4EE-9B6D-4FF8-A3EC-1AB554F51F78Q33673122-61EAE384-9FE2-49A0-ADAD-19BCD0F11612Q33920606-C1F0E8FB-FBA7-4B9A-A8F9-3B2CA481AAB5Q34254787-73F9D7C4-6E3C-4198-91A1-807A3D6E8918Q34284547-987359FC-D61C-4108-85CE-4225492C669FQ34410378-FD5F62CF-9FE6-469D-BA15-BBADCAB48411Q34495145-68F9B00D-2202-4D27-8CAA-F90AAC497FDCQ34614524-14E4FB58-249C-42CB-AFD4-2A2736761F4DQ34769805-5B5D889A-E3D1-4977-B4F4-4F75C421BB50Q35051785-3337DBBD-345A-4B2D-850C-F18E19DC77D6Q35125473-04B8C89B-875E-4924-ABEB-DE5C274E4284Q35161241-7A79041E-0BE3-42AA-9E3D-485F05561BC9Q35561308-8E60E7FF-80A4-4DD7-AA43-059D880A2388Q35572682-3D214D69-0E9E-4E20-931C-D7B8E47D8C22Q35864666-A03A9EE5-225D-4696-AAF0-94ADCFE073D0Q35910429-A070675A-E78D-4776-B857-33341E9EE62EQ36301573-AC544F08-AA03-4F55-B381-F238637376BEQ36316126-C4D0FD5C-1011-44C0-8DDD-D128F66B210BQ36329913-6ACDC5F5-2F7B-4112-97F5-C9B849F72385Q36331717-9947E5FD-F8BA-48C0-BB0B-9F4EF541FB93Q36652827-ACE0F36F-B089-4FA6-A477-4C06FD0B7787Q36929947-EBC0256F-77B7-44D0-A500-4BCB2EFABD71Q36945255-5AE95653-5F36-47CF-A1E6-7D3C88D06A26Q36996546-95ACD2A1-A173-4170-8F92-A8779FB8585FQ37036416-BC28BA79-1C2D-400A-A800-98CF7F890470Q37055585-60B53CF1-8526-4763-A087-CAEA0E885146Q37102216-101B48E2-0D83-4B49-BABE-4E14A43A2564Q37241722-9B1277BF-42A7-4AC0-9B85-FB53FCDCCD6BQ37510565-FEB062AC-B4B5-4F29-A5C1-9F35D3F368A8Q37721962-DC0CFFE5-241A-464D-9FDD-F6A4AED03838Q37732688-E2F131EF-F0DE-4782-9C15-BFC08EED15E6Q37771798-A9C96366-B265-40D9-957E-8464B72D30B0Q38096980-5494546A-D8CD-48CD-809E-AC55AB9CE893Q38164656-B6A5A702-20CC-4F79-AAEB-225279FD888DQ38584636-E0B9A240-8F12-4766-9E05-5C8D81BB3DEFQ38604382-5A713CC2-51AE-4D7E-8535-93538D584625
P2860
Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus
@ast
Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus
@en
Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus
@en-gb
Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus
@nl
type
label
Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus
@ast
Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus
@en
Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus
@en-gb
Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus
@nl
altLabel
Risk of fatal and nonfatal lac ...... matic review and meta-analysis
@en
prefLabel
Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus
@ast
Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus
@en
Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus
@en-gb
Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus
@nl
P2093
P31
P1476
Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus
@en
P2093
Elizabeth Greyber
Gary A. Pasternak
Shelley R. Salpeter
P356
10.1001/ARCHINTE.163.21.2594
P407
P577
2003-11-24T00:00:00Z